All In Biotech

Drug Trial Radar · NCT01464905

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

A Phase 3, Multicenter, Double-blind,Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of NU100 in Patients With Relapsing Forms of Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Sep 23, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

500

Planned (sponsor's estimate)

Start

Oct 2011

Primary completion

Dec 2013

Study completion Dec 2014

Sponsor

Lead sponsor
Nuron Biotech Inc.Industry
Sponsor type
Industry
First posted
Nov 4, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of NU100 in patients with relapsing remitting multiple sclerosis (RRMS) as compared to placebo and an active comparator. The primary clinical objective selected for this Phase 3 study, the cumulative number of new combined unique active lesions (CALs; defined as new gadolinium T1-weighted lesions and non-enhancing new and newly enlarging T2-weighted lesions) on magnetic resonance imaging (MRI) scans over the course of 4 and 12 months of treatment to demonstrate the superiority of NU100 to placebo and the non-inferiority of NU100 to Betaferon®, respectively.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

  • NU100Biological

    0.25 mg SQ, every other day for 12 months

  • PlaceboBiological

    1 mL SQ, every other day for 4 months

  • rhIFN beta-1bBiological

    0.25 mg SQ, every other day for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. New CALs after 4 months of treatment based on the MRI outcomes obtained at 4 and 12 monthsTime frame: 2 to 12 months

Locations

12 sites in 12 countries. Site status is shown where the registry gives one.

  • Site not named

    Minsk, Belarus

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Zagreb, Croatia

  • Site not named

    Tbilisi, Georgia

  • Site not named

    Budapest, Hungary

  • Site not named

    Rome, Italy

  • Site not named

    Beirut, Lebanon

  • Site not named

    Warsaw, Poland

  • Site not named

    Moscow, Russia

  • Site not named

    Belgrade, Serbia

  • Site not named

    Barcelona, Spain

  • Site not named

    Kiev, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.